摘要
目的:探讨重组人表皮生长因子面膜在SPECTRA10调Q激光治疗面部雀斑中的应用。方法:选择2017年2月-2019年10月在笔者医院皮肤科接受治疗的73例面部雀斑患者为研究对象,随机分为35例对照组和38例治疗组。对照组接受SPECTRA10调Q激光治疗,治疗组在对照组基础上给予重组人表皮生长因子面膜,观察并对比两组临床疗效、视觉模拟评分(VAS)、激光治疗区皮损反应时间、术后并发症和复发情况。结果:治疗组有效率高于对照组(P<0.05)。术后即刻,两组VAS评分比较差异无统计学意义(P>0.05);术后1d,治疗组VAS评分低于对照组(P<0.05)。治疗组激光治疗区皮肤皮损反应时间(1.59±0.21)d,少于对照组的(2.48±0.35)d,两组比较差异有统计学意义(P<0.05)。两组术区皮肤均有灼痛、发红、未发生继发感染、水疱及瘢痕等,对照组有4例患者发生暂时性色素沉着,治疗组有1例患者发生暂时性色素沉着,差异无统计学意义(P>0.05)。术后6个月,对照组有1例患者复发,治疗组无复发,两组比较差异无统计学意义(P>0.05)。结论:重组人表皮生长因子面膜能够提高SPECTRA10调Q激光治疗面部雀斑的效果,减轻激光治疗后疼痛和皮损反应。
Objective To explore the application of recombinant human epidermal growth factor mask in SPECTRA10 Q-switched laser treatment of facial freckles. Methods 73 patients with facial freckles who were treated in the dermatology department of our hospital from February 2017 to October 2019 were selected as the research object and randomly divided into 35 control groups and 38 treatment groups. The control group received SPECTRA10 Q-switched laser treatment. The treatment group received recombinant human epidermal growth factor mask on the basis of the control group. The clinical efficacy, visual analogue scale(VAS), reaction time of skin lesions in laser treatment area,postoperative complications and recurrence were observed and compared between the two groups. Results The effective rate of the treatment group was higher than that of the control group(P<0.05). Immediately after operation,there was no significant difference in VAS scores between the two groups(P>0.05). On the 1 st day after operation,the VAS score in the treatment group was lower than that in the control group(P<0.05). The response time of skin lesions in laser treatment area of treatment group was lesser than that of control group(1.59±0.21) d vs(2.48±0.35)d(P<0.05). There were burning pain and redness on the skin in the operation area of the two groups, and no secondary infection, blisters, scars and the like occurred. in the control group, 4 patients had temporary pigmentation, while in the treatment group, 1 patient had temporary pigmentation, there was no statistical difference(P>0.05). In the control group, one patient relapsed 6 months after operation, while in the treatment group, there was no relapse, and there was no statistical difference between the two groups(P>0.05). Conclusion Recombinant human epidermal growth factor facial mask can improve the effect of SPECTRA10 Q-switched laser in the treatment of facial freckles, and reduce the pain and skin lesion reaction after laser surgery.
作者
李欢
喻路
LI Huan;YU Lu(Department of Dermatology,Dazu District People's Hospital,Chongqing 402360,China)
出处
《中国美容医学》
CAS
2021年第11期78-80,共3页
Chinese Journal of Aesthetic Medicine
